AMPH Amphastar Pharmaceuticals PE ratio, current and historical analysis
The P/E ratio for Amphastar Pharmaceuticals stock stands at 7.1 as of Apr 17, 2025. This is calculated based on the current EPS of $3.29 and the stock price of $23.35 per share. A decrease of 45% has been recorded in the PE ratio compared to the average of 12.9 of the past four quarters.
AMPH PE ratio history
Over the last ten years, the average PE ratio of Amphastar Pharmaceuticals has been 131.05. The current 7.1 price-to-earnings ratio is 95% less than the historical average. In the past ten years, AMPH's PE ratio reached its highest point in the Mar 2016 quarter at 1,200, with a price of $12 and an EPS of $0.01. The Dec 2024 quarter saw the lowest point at 11.29, with a price of $37.13 and an EPS of $3.29.
Amphastar Pharmaceuticals PE ratio by year
Maximum annual increase: 3,513.64% in 2020
Maximum annual decrease: -97.33% in 2021
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 11.29 | -47.97% | $37.13 | $3.29 |
| 2023 | 21.7 | 45.64% | $61.85 | $2.85 |
| 2022 | 14.9 | -16.85% | $28.02 | $1.88 |
| 2021 | 17.92 | -97.33% | $23.29 | $1.3 |
| 2020 | 670.33 | 3,513.64% | $20.11 | $0.03 |
| 2019 | 18.55 | N/A | $19.29 | $1.04 |
| 2018 | N/A | N/A | $19.9 | -$0.12 |
| 2017 | 240.5 | 187.23% | $19.24 | $0.08 |
| 2016 | 83.73 | N/A | $18.42 | $0.22 |
| 2015 | N/A | N/A | $14.23 | -$0.06 |
| 2014 | N/A | N/A | $11.61 | -$0.25 |
| 2013 | N/A | N/A | N/A | $0.31 |
| 2012 | N/A | N/A | N/A | $0.47 |
| 2011 | N/A | N/A | N/A | $0.2 |
Amphastar Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | 11.29 | -24.38% | $37.13 | $3.29 |
| Sep 2024 | 14.93 | 28.04% | $48.53 | $3.25 |
| Jun 2024 | 11.66 | -15.01% | $40 | $3.43 |
| Mar 2024 | 13.72 | -36.77% | $43.91 | $3.2 |
| Dec 2023 | 21.7 | 31.67% | $61.85 | $2.85 |
| Sep 2023 | 16.48 | -39.79% | $45.99 | $2.79 |
| Jun 2023 | 27.37 | 39.43% | $57.47 | $2.1 |
| Mar 2023 | 19.63 | 31.74% | $37.5 | $1.91 |
| Dec 2022 | 14.9 | -16.2% | $28.02 | $1.88 |
| Sep 2022 | 17.78 | -3.94% | $28.1 | $1.58 |
| Jun 2022 | 18.51 | -12.85% | $34.79 | $1.88 |
| Mar 2022 | 21.24 | 18.53% | $35.9 | $1.69 |
| Dec 2021 | 17.92 | -28.35% | $23.29 | $1.3 |
| Sep 2021 | 25.01 | -72.71% | $19.01 | $0.76 |
| Jun 2021 | 91.64 | -69.99% | $20.16 | $0.22 |
AMPH average PE ratio chart
Currently, AMPH's PE ratio is lower than the 3, 5 and 10-year averages.
AMPH PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| AMPH Amphastar Pharmaceuticals Inc | 7.07 | $1.11B |
| SCYX Scynexis Inc | N/A | $35.87M |
| RGLS Regulus Therapeutics Inc | N/A | $133.15M |
Frequently asked questions
What is Amphastar Pharmaceuticals's PE ratio?
The price to earnings ratio for AMPH stock is 7.1 as of Apr 17, 2025.
What is the 3-year average PE ratio for Amphastar Pharmaceuticals (AMPH)?
The average PE ratio for AMPH stock over the past 3 years is 17.09.
What is the 5-year average PE ratio for Amphastar Pharmaceuticals (AMPH)?
The average PE ratio for AMPH stock over the past 5 years is 87.84.
What is the highest PE ratio for AMPH?
The highest quarterly PE ratio in the last ten years has been 1,200 and it was in the Mar 2016 quarter.
How does the current PE ratio for AMPH compare to its historical average?
The current price to earnings ratio of AMPH is 95% lower than the 10-year historical average.
Why is Amphastar Pharmaceuticals's PE ratio so low?
AMPH's stock price is trading at a lower multiple of earnings, which is why its PE ratio of 7.1 is considered low.
How is AMPH's PE ratio calculated (Amphastar Pharmaceuticals PE ratio formula)?
The P/E ratio is calculated by dividing the latest price of a stock by its trailing twelve months EPS. As of today (Apr 17, 2025), Amphastar Pharmaceuticals's stock price is $23.35. The earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $3.29. Therefore, Amphastar Pharmaceuticals's price to earnings ratio for today is 7.1. PE RATIO(7.1) = STOCK PRICE($23.35) / TTM EPS($3.29)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.